141 related articles for article (PubMed ID: 38330165)
1. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
[TBL] [Abstract][Full Text] [Related]
2. Extensive expertise in endocrinology: glucose-dependent insulinotropic peptide-dependent Cushing's syndrome.
Lacroix A
Eur J Endocrinol; 2023 Mar; 188(3):R56-R72. PubMed ID: 36857084
[TBL] [Abstract][Full Text] [Related]
3. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.
Hage M; Chaligné R; Viengchareun S; Villa C; Salenave S; Bouligand J; Letouzé E; Tosca L; Rouquette A; Tachdjian G; Parker F; Lombès M; Lacroix A; Gaillard S; Chanson P; Kamenický P
J Clin Endocrinol Metab; 2019 May; 104(5):1777-1787. PubMed ID: 30376114
[TBL] [Abstract][Full Text] [Related]
5. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study.
Chasseloup F; Bourdeau I; Tabarin A; Regazzo D; Dumontet C; Ladurelle N; Tosca L; Amazit L; Proust A; Scharfmann R; Mignot T; Fiore F; Tsagarakis S; Vassiliadi D; Maiter D; Young J; Lecoq AL; Deméocq V; Salenave S; Lefebvre H; Cloix L; Emy P; Dessailloud R; Vezzosi D; Scaroni C; Barbot M; de Herder W; Pattou F; Tétreault M; Corbeil G; Dupeux M; Lambert B; Tachdjian G; Guiochon-Mantel A; Beau I; Chanson P; Viengchareun S; Lacroix A; Bouligand J; Kamenický P
Lancet Diabetes Endocrinol; 2021 Dec; 9(12):813-824. PubMed ID: 34655521
[TBL] [Abstract][Full Text] [Related]
6. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of
Regazzo D; Losa M; Albiger NM; Terreni MR; Vazza G; Ceccato F; Emanuelli E; Denaro L; Scaroni C; Occhi G
Eur J Endocrinol; 2017 May; 176(5):543-553. PubMed ID: 28179449
[TBL] [Abstract][Full Text] [Related]
7. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
Hage M; Janot C; Salenave S; Chanson P; Kamenický P
Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
[TBL] [Abstract][Full Text] [Related]
8. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
[TBL] [Abstract][Full Text] [Related]
9. The Methylation Analysis of the
Dalle Nogare M; D'Annunzio S; Vazza G; Regazzo D; Picello L; Denaro L; Voltan G; Scaroni C; Ceccato F; Occhi G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298217
[TBL] [Abstract][Full Text] [Related]
10. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
12. Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome.
Lecoq AL; Stratakis CA; Viengchareun S; Chaligné R; Tosca L; Deméocq V; Hage M; Berthon A; Faucz FR; Hanna P; Boyer HG; Servant N; Salenave S; Tachdjian G; Adam C; Benhamo V; Clauser E; Guiochon-Mantel A; Young J; Lombès M; Bourdeau I; Maiter D; Tabarin A; Bertherat J; Lefebvre H; de Herder W; Louiset E; Lacroix A; Chanson P; Bouligand J; Kamenický P
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931750
[TBL] [Abstract][Full Text] [Related]
13. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.
Ben-Shlomo A; Deng N; Ding E; Yamamoto M; Mamelak A; Chesnokova V; Labadzhyan A; Melmed S
J Clin Invest; 2020 Nov; 130(11):5738-5755. PubMed ID: 32673291
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
[TBL] [Abstract][Full Text] [Related]
15. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
[TBL] [Abstract][Full Text] [Related]
16. Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
Oba-Yamamoto C; Kameda H; Miyoshi H; Sekizaki T; Takase T; Yanagimachi T; Fujita Y; Nomoto H; Cho KY; Nakamura A; Nagai S; Atsumi T
Intern Med; 2021; 60(15):2375-2383. PubMed ID: 34334589
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
18. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
19. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
20. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
